DE-ESCALATING THERAPY IN PATIENTS WITH CROHN'S DISEASE RECEIVING ADALIMUMAB: SUBGROUP ANALYSIS OF THE CALM STUDY

被引：1
|
作者：
Bossuyt, P. [1 ]
D'Haens, G. [2 ]
Panaccione, R. [3 ]
Sandborn, W. [4 ]
Reinisch, W. [5 ]
Travis, S. [6 ]
Schreiber, S. [7 ]
Armuzzi, A. [8 ]
Danese, S. [9 ]
Berg, S. [10 ]
Petersson, J. [11 ]
Maa, J-F [11 ]
Neimark, E. [11 ]
Colombel, F. [12 ]
机构：
[1] Imelda Gen Hosp, Bonheiden, Belgium
[2] Acad Med Ctr, Amsterdam, Netherlands
[3] Univ Calgary, Calgary, AB, Canada
[4] Univ Calif San Diego, La Jolla, CA 92093 USA
[5] Med Univ Vienna, Vienna, Austria
[6] Oxford Univ Hosp, Oxford, England
[7] Univ Hosp Schleswig Holstein, Kiel, Germany
[8] Fdn Policlin Gemelli Univ, Rome, Italy
[9] Humanitas Univ, Rozzano, Italy
[10] AbbVie, Solna, Sweden
[11] AbbVie Inc, N Chicago, IL USA
[12] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
GUT | 2019年 / 68卷
关键词：
D O I：
10.1136/gutjnl-2019-BSGAbstracts.136
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
PTH-077
引用
收藏
页码：A70 / A71
页数：2
相关论文
共 50 条
  • [41] Epigenetic and gene expression changes in patients with Crohn's disease, and responsiveness to adalimumab therapy
    Celesnik, H.
    Koder, S.
    Potocnik, U.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 739 - 739
  • [42] Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease
    Veerappan, Sundaram G.
    Healy, Martin
    Walsh, Bernard J.
    O'Morain, Colm A.
    Daly, Jacqueline S.
    Ryan, Barbara M.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (07) : 2119 - 2129
  • [43] Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn’s Disease
    Sundaram G. Veerappan
    Martin Healy
    Bernard J. Walsh
    Colm A. O’Morain
    Jacqueline S. Daly
    Barbara M. Ryan
    Digestive Diseases and Sciences, 2015, 60 : 2119 - 2129
  • [44] Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn's disease
    Feagan, Brian
    Loftus, Edward
    Johnson, Scott
    Wu, Eric
    Yu, Andrew
    Chao, Jingdong
    Mulani, Parvez
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S383 - S383
  • [45] Miliary tuberculosis during adalimumab therapy in Crohn's disease
    Ameneiros-Lago, Eugenia
    Vazquez Bueno, Jose Angel
    Garrido Sanjuan, Juan Antonio
    MEDICINA CLINICA, 2018, 150 (10): : 412 - 412
  • [46] Leukocytoclastic Vasculitis Associated with Adalimumab Therapy for Crohn's Disease
    Xu, Lankai Cathy
    Grandhe, Sirisha
    Marsano, Joseph G.
    CASE REPORTS IN GASTROENTEROLOGY, 2022, 17 (01) : 143 - 147
  • [47] Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease
    Ribaldone, Davide Giuseppe
    Caviglia, Gian Paolo
    Abdulle, Amina
    Pellicano, Rinaldo
    Ditto, Maria Chiara
    Morino, Mario
    Fusaro, Enrico
    Saracco, Giorgio Maria
    Bugianesi, Elisabetta
    Astegiano, Marco
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [48] 2 YEAR FOLLOW-UP OF ADALIMUMAB THERAPY IN PATIENTS WITH CROHN'S DISEASE
    Kemp, K.
    Dibb, M.
    Makin, A. J.
    Campbell, S. S.
    GUT, 2009, 58 : A64 - A64
  • [49] Impact of adalimumab therapy on bone metabolism in Crohn's disease patients: A 3 months follow up study
    Veerappan, S. G.
    Healy, M.
    Walsh, B.
    Kennedy, M.
    O'Morain, C. A.
    Ryan, B. M.
    Daly, J. S.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S94 - S94
  • [50] Adalimumab and Infliximab As Induction Therapy for Crohn's Disease - A Prospective Observational Study in Germany
    Bokemeyer, Bernd
    Helwig, Ulf
    Teich, Niels
    Schmidt, Carsten
    Krummenerl, Thomas
    Rupf, Ann-Katrin
    Hartmann, Heinz
    Blaker, Michael
    Krummenerl, Annette
    Duffelmeyer, Marc
    Hinrichs, Regina
    Hartmann, Petra
    Nikolaus, Susanna
    Huppe, Dietrich
    Schreiber, Stefan
    GASTROENTEROLOGY, 2014, 146 (05) : S453 - S453
12345